Passive Transdermal Systems Whitepaper Incorporating Current Chemistry, Manufacturing and Controls (CMC) Development Principles

In this whitepaper, the Manufacturing Technical Committee (MTC) of the Product Quality Research Institute has updated the 1997 Transdermal Drug Delivery Systems Scale-Up and Post Approval Change workshop report findings to add important new product development and control principles. Important topic...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Buskirk, Glenn A., Arsulowicz, Daniel, Basu, Prabir, Block, Lawrence, Cai, Bing, Cleary, Gary W., Ghosh, Tapash, González, Mario A., Kanios, David, Marques, Margareth, Noonan, Patrick K., Ocheltree, Terrance, Schwarz, Peter, Shah, Vinod, Spencer, Thomas S., Tavares, Lino, Ulman, Katherine, Uppoor, Rajendra, Yeoh, Thean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
White Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3279638/
https://www.ncbi.nlm.nih.gov/pubmed/22215291
http://dx.doi.org/10.1208/s12249-011-9740-9
Descripción
Sumario:In this whitepaper, the Manufacturing Technical Committee (MTC) of the Product Quality Research Institute has updated the 1997 Transdermal Drug Delivery Systems Scale-Up and Post Approval Change workshop report findings to add important new product development and control principles. Important topics reviewed include ICH harmonization, quality by design, process analytical technologies, product and process validation, improvements to control of critical excipients, and discussion of Food and Drug Administration’s Guidance on Residual Drug in Transdermal and Related Drug Delivery Systems as well as current thinking and trends on in vitro–in vivo correlation considerations for transdermal systems.

Ejemplares similares